Agnès Bénardeau

Agnès Bénardeau

Company: Novo Nordisk

Job title: Senior Director, Head of Cardio-Renal Biology


Interrogating Translatability of In Vitro to In Vivo Models to Select Appropriate Kidney Models & Predict Efficacy 11:30 am

Acute Kidney Injury (AKI): How does the multitude of AKI models relate to patient disease? Which readouts matter the most? Could cellular assays help to optimize the in vitro to in vivo models translatability?Read more

day: Track 1 - Day 2 AM

Panel Discussion: How can we Modernize Surrogate Endpoint Development? Moving Beyond Hard Endpoints 8:00 am

Evaluating novel surrogate endpoints in addition to emerging standard of care Non-invasive imaging, patient-reported outcomes, UACR, and more: what is an acceptable endpoint? Considering payers perspectives’ on moving beyond hard endpoints and ESRDRead more

day: Day One

Panel Discussion: How Can We Invigorate AKI Drug Development? Identifying Novel Targets & Establishing a Pathway to Surmount Challenges in Biomarkers & Precision Medicine 2:30 pm

What can we learn from clinical setbacks in AKI? Addressing translational barriers in AKI: optimizing models to predict efficacy and biomarkers of therapeutic target engagement Characterizing endophenotypes through omics approaches to enable comprehensive, longitudinal understanding of AKIRead more

day: Seminar Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.